Cirtuvivint for advanced soft-tissue sarcomas
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called Cirtuvivint for people with certain advanced soft-tissue sarcomas that have grown recently. It aims to see if the drug can stop or slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 70 years old.
- You have one of these sarcoma types: solitary fibrous tumor, synovial sarcoma, clear cell sarcoma, extraskeletal myxoid chondrosarcoma, alveolar soft part sarcoma, myxoid liposarcoma, or desmoid tumor.
- Your sarcoma has grown or spread in the last 6 months.
- You have had at least one type of chemotherapy (anthracyclines) before, unless you have solitary fibrous tumor.
- You are willing to provide a tumor sample and blood samples for study purposes.
- You have a good performance status (ECOG 0-1) and adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two injectable medications (OVV-01 and AK112) combined together to treat advanced soft tissue sarcoma—a cancer that has spread or cannot be surgically removed—in patients whose previous treatments have failed. The goal is to see if injecting these drugs directly into tumors can help shrink them and improve outcomes.
This trial tests a new combination of radiation therapy and an immunotherapy approach (called PraG) for people with advanced soft tissue sarcoma that can't be removed by surgery or has spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial combines cryoablation (a freezing technique to destroy tumors) with camrelizumab (an immunotherapy drug that helps your immune system fight cancer) for patients with advanced soft tissue sarcoma that hasn't responded to standard treatments. The goal is to see if this combination works better than current options.
This trial tests a combination of targeted therapy, chemotherapy, and radiation for advanced soft tissue sarcoma that has not responded to standard treatment. It aims to see if the combination can help patients live longer or shrink their tumors.
This trial tests a new drug called HS-20093 combined with other treatments for people with advanced bone or soft tissue sarcoma. It aims to find safe and effective combinations for those who haven't responded to standard treatments.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Hear when a new Soft Tissue Sarcoma (STS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.